Neovasc Inc.

Latest

Sep 30, 2019, 08:55 ET Neovasc's Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Sep 23, 2019, 08:55 ET Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina to be Featured at TCT 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 23, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Sep 16, 2019, 08:55 ET Neovasc Announces Changes to its Board of Directors

Norman Radow, Managing Partner at Strul Medical Group, Joins Company's Board NASDAQ, TSX: NVCN VANCOUVER, Sept. 16, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a...


Sep 04, 2019, 08:55 ET Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 4, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Sep 03, 2019, 08:55 ET The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

Announcement Made at European Society of Cardiology Congress 2019 in Paris, France NASDAQ, TSX: NVCN VANCOUVER, Sept. 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a ...


Aug 22, 2019, 08:55 ET Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

NASDAQ, TSX: NVCN VANCOUVER, Aug. 22, 2019 /CNW/ - ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The ...


Aug 07, 2019, 16:01 ET Neovasc Announces Second Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet...


Aug 05, 2019, 08:55 ET Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference

Presentation Scheduled for 11:30 am Eastern Time on August 8th NASDAQ, TSX: NVCN VANCOUVER, Aug. 5, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the...


Aug 02, 2019, 08:55 ET Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th

Conference Call Scheduled for 4:30 pm Eastern Time on August 7th NASDAQ, TSX: NVCN VANCOUVER, Aug. 2, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the...


Jul 17, 2019, 15:04 ET Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

NASDAQ, TSX: NVCN VANCOUVER, July 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jul 16, 2019, 08:55 ET Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Pending U.S. Food and Drug Administration ("FDA") Humanitarian Use Device ("HUD") Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early 2020 A...


Jul 15, 2019, 16:11 ET Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

Company Joined by Other Industry Leaders as Part of ISO Cardiac Valves Working Group NASDAQ, TSX: NVCN VANCOUVER, July 15, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: ...


Jul 12, 2019, 08:55 ET Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

NASDAQ, TSX: NVCN VANCOUVER, July 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 28, 2019, 07:00 ET Neovasc Announces Effective Date of Share Consolidation

NASDAQ, TSX: NVCN VANCOUVER, June 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 27, 2019, 08:55 ET Neovasc Announces Presentations on Tiara™ for Treatment of Mitral Regurgitation and Reducer™ for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, June 27, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 25, 2019, 14:30 ET Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN VANCOUVER, June 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 17, 2019, 08:55 ET Tiara™ Featured in Presentation at 11th Annual TVT 2019

NASDAQ, TSX: NVCN VANCOUVER, June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


Jun 07, 2019, 13:30 ET Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

NASDAQ, TSX: NVCN VANCOUVER, June 7, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of...


Jun 04, 2019, 14:15 ET Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, June 4, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual...


May 28, 2019, 08:55 ET Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, May 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 23, 2019, 09:17 ET New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

NASDAQ, TSX: NVCN VANCOUVER, May 23, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 22, 2019, 17:30 ET Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

NASDAQ, TSX: NVCN VANCOUVER, May 22, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve...


May 16, 2019, 20:00 ET Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

NASDAQ, TSX: NVCN VANCOUVER, May 16, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN) announced today that it has closed its previously announced private placement (the...


May 14, 2019, 07:00 ET Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

Upon closing of this agreement, cash and cash equivalents is expected to support operations into Q1 2020 NASDAQ, TSX: NVCN VANCOUVER, May 14, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company")...


May 09, 2019, 16:00 ET Neovasc Announces First Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights Announced the 1,000th recipient of a Neovasc ReducerTM ("Reducer") implant Company sponsored Reducer Symposium attended by over 100 attendees at the 85th Annual...